APA-Zitierstil (7. Ausg.)

Stein, A. M., & Müller, M. C. (2013). Rapid initial decline in BCR-ABL1 is associated with superior responses to second-line nilotinib in patients with chronic-phase chronic myeloid leukemia. BMC cancer, 13, .

Chicago-Zitierstil (17. Ausg.)

Stein, Andrew M., und Martin Christian Müller. "Rapid Initial Decline in BCR-ABL1 Is Associated with Superior Responses to Second-line Nilotinib in Patients with Chronic-phase Chronic Myeloid Leukemia." BMC Cancer 13 (2013).

MLA-Zitierstil (9. Ausg.)

Stein, Andrew M., und Martin Christian Müller. "Rapid Initial Decline in BCR-ABL1 Is Associated with Superior Responses to Second-line Nilotinib in Patients with Chronic-phase Chronic Myeloid Leukemia." BMC Cancer, vol. 13, 2013.